Display options
Cite
Raghuthaman G, Venkateswaran R, Krishnadas R. Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial. BJPsych Open. 2015;1(2):172-177doi: 10.1192/bjpo.bp.115.001248.
Raghuthaman, G., Venkateswaran, R., & Krishnadas, R. (2015). Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial. BJPsych open, 1(2), 172-177. https://doi.org/10.1192/bjpo.bp.115.001248
Raghuthaman, G, et al. "Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial." BJPsych open vol. 1,2 (2015): 172-177. doi: https://doi.org/10.1192/bjpo.bp.115.001248
Raghuthaman G, Venkateswaran R, Krishnadas R. Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial. BJPsych Open. 2015 Dec 14;1(2):172-177. doi: 10.1192/bjpo.bp.115.001248. eCollection 2015 Oct. PMID: 27703744; PMCID: PMC4998932.
Copy Download .nbib Format: NLM
Share it on

BJPsych Open. 2015 Dec 14;1(2):172-177. doi: 10.1192/bjpo.bp.115.001248. eCollection 2015 Oct.

Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial.

BJPsych open

G Raghuthaman, R Venkateswaran, R Krishnadas

Affiliations

  1. , MBBS, DPM, MD, Department of Psychiatry, PSG Institute of Medical Sciences and Research, Coimbatore, India.
  2. , MBBS, MD, Department of Child Psychiatry, CMC, Vellore, India.
  3. , MBBS, MD, MRCPsych, PhD, ESTEEM, NHS Greater Glasgow and Clyde, Glasgow, UK.

PMID: 27703744 PMCID: PMC4998932 DOI: 10.1192/bjpo.bp.115.001248

Abstract

BACKGROUND: Hyperprolactinaemia is a troublesome side-effect of treatment with antipsychotics.

AIMS: This double-blind, placebo-controlled study aimed at examining the effect of adjunctive treatment with 10 mg aripiprazole on prolactin levels and sexual side-effects in patients with schizophrenia symptomatically maintained on risperidone.

METHOD: Thirty patients taking risperidone were enrolled into the trial (CTRI/2012/11/003114). Aripiprazole was administered at a fixed daily dose of 10 mg/day for 8 weeks. Serum prolactin was measured at baseline and at 8 weeks. Hyperprolactinaemia-related problems, psychopathology and side-effects were evaluated every 2 weeks.

RESULTS: Prolactin levels decreased by 58% in the aripiprazole group compared with an increase by 22% in the placebo group. Prolactin levels normalised in 46% of patients in the aripiprazole group (number needed to treat, NNT=2). Aripiprazole improved erectile dysfunction in five out of six patients. There were no significant differences in change in psychopathology or side-effects between groups.

CONCLUSIONS: Adjunctive aripiprazole reduced prolactin levels in those treated with risperidone, with no effect on psychopathology and extrapyramidal symptoms. This is a potential treatment for hyperprolactinaemia observed during treatment with second-generation antipsychotics.

DECLARATION OF INTEREST: None.

COPYRIGHT AND USAGE: © The Royal College of Psychiatrists 2015. This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) licence.

References

  1. Int J Neuropsychopharmacol. 2012 Jun;15(5):645-56 - PubMed
  2. BMJ. 2014 May 23;348:g3207 - PubMed
  3. CNS Drugs. 2014 May;28(5):421-53 - PubMed
  4. J Clin Psychopharmacol. 2005 Feb;25(1):26-31 - PubMed
  5. Psychopharmacology (Berl). 2013 Jul;228(2):175-85 - PubMed
  6. Am J Psychiatry. 2011 Sep;168(9):947-56 - PubMed
  7. Curr Pharm Des. 2010;16(5):488-501 - PubMed
  8. BMC Psychiatry. 2012 Mar 30;12:27 - PubMed
  9. Neuropsychopharmacology. 2003 Aug;28(8):1400-11 - PubMed
  10. Hum Psychopharmacol. 2006 Dec;21(8):529-32 - PubMed
  11. Am J Psychiatry. 2007 Sep;164(9):1404-10 - PubMed
  12. J Clin Psychopharmacol. 2009 Aug;29(4):394-5 - PubMed
  13. Neuropsychopharmacology. 2006 Sep;31(9):1854-63 - PubMed
  14. Br J Psychiatry. 1989 May;154:672-6 - PubMed
  15. Psychiatry Clin Neurosci. 2010 Feb;64(1):19-27 - PubMed
  16. Psychoneuroendocrinology. 2006 Apr;31(3):340-6 - PubMed
  17. J Sex Marital Ther. 2000 Jan-Mar;26(1):25-40 - PubMed
  18. J Sex Marital Ther. 2003 Jul-Aug;29(4):289-96 - PubMed
  19. J Clin Psychiatry. 2004 Jan;65(1):57-61 - PubMed
  20. N Engl J Med. 2003 Nov 20;349(21):2035-41 - PubMed
  21. J Clin Psychiatry. 2009 Oct;70(10):1348-57 - PubMed
  22. J Clin Psychiatry. 2004 Feb;65(2):187-90 - PubMed
  23. Sci Rep. 2015 Mar 10;5:8902 - PubMed
  24. BMC Psychiatry. 2008 Dec 22;8:95 - PubMed
  25. BMJ. 2010 Mar 23;340:c869 - PubMed
  26. PLoS One. 2013 Aug 01;8(8):e70179 - PubMed
  27. J Endocrinol. 1989 Apr;121(1):157-66 - PubMed
  28. Harv Rev Psychiatry. 2007 Sep-Oct;15(5):245-58 - PubMed
  29. Br J Psychiatry. 1974 May;124(0):420-30 - PubMed
  30. Lancet. 2013 Sep 14;382(9896):951-62 - PubMed
  31. J Clin Psychiatry. 2005 Jun;66(6):761-7 - PubMed
  32. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Dec 1;34(8):1495-9 - PubMed
  33. J Clin Psychopharmacol. 2010 Oct;30(5):596-9 - PubMed
  34. Br J Psychiatry. 1974 May;124(0):413-9 - PubMed
  35. Acta Psychiatr Scand Suppl. 1970;212:11-9 - PubMed
  36. CNS Drug Rev. 2004 Winter;10(4):317-36 - PubMed
  37. Neuropsychopharmacology. 2007 Jan;32(1):67-77 - PubMed

Publication Types